Navigation Links
Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
Date:11/10/2011

WARRENDALE, Pa., Nov. 10, 2011 /PRNewswire/ -- Bayer HealthCare's affiliate MEDRAD, Inc. today announced that five-year data from the THUNDER trial* demonstrated a 59 percent relative reduction in target lesion revascularization (TLR) rates in popliteal arteries of patients with peripheral arterial disease (PAD) treated with the Cotavance® drug eluting balloon with Paccocath® technology compared to standard balloon angioplasty (POBA). Additionally, for patients requiring TLR, the average time to revascularization before TLR was extended by 448 days in patients treated with the Cotavance catheter, which is available in Europe, but not yet approved in the U.S. MEDRAD is currently moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

The data were presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco as part of a TCT-sponsored symposium titled, "Drug-Coated Balloons: Clinical Data and Applications."

"These data with Bayer HealthCare's Paccocath technology represent the only five-year clinical TLR outcomes in comparison to standard balloons," said Prof. Dr. med. Gunnar Tepe of Klinikum Rosenheim in Rosenheim, Germany, principal investigator of THUNDER. "The results demonstrate clear long-term benefits for patients with the Cotavance paclitaxel eluting balloon for reducing the number of TLR procedures and extending the time before a revascularization might be needed in PAD patients." Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, who presented the data at the TCT symposium, added, "Beginning as early as the first year and continuing through year five, a consistent 30 to 40 percent improvement was seen with the Cotavance catheter in avoiding TLR. TCT was an excellent venue to share these ground-breaking data."

D
'/>"/>

SOURCE Bayer HealthCare-MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
2. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
5. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
8. Neptune Products to be commercialized by BAYER HealthCare
9. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
10. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
11. Bayer CropScience Announces Investment of $25 Million for Institute Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Israel, April 28 ITGI Medical, Ltd.,(TASE: ITGI) ... of heterologous tissue covered stents, announced that the ... (Humanitarian Use Device),designation to Over and Under(R) and ... dissections of native coronary arteries and,Saphenous Vein Grafts. ...
... Mich., April 28 The following news advisory is ... Business Meeting - During the meeting an important development ... MichBio, Michigan,s trade association for the bioscience industry When: ... Reception , 6:30 p.m. Dinner , 7:00 p.m. Meeting ...
... also Initiates the Phase 2b ASTUTE Clinical Trial for ... Inc., a privately held biopharmaceutical company, announced that data ... treatment of patients with low-grade hepatic encephalopathy was presented ... European Association for the Study of Liver Disease (EASL) ...
Cached Biology Technology:Key Industry-Relevant Development to be Announced at MichBio's 2009 Annual Meeting on May 6 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... climate change projected this century for Oregon,s Upper ... supplies, buildings, transportation systems, human health, forests, and ... by the University of Oregon,s Climate Leadership Initiative ... Policy. The authors say that extensive efforts ...
... toward renewable energy, questions persist about the Earth,s climate. ... natural variations in climate or other causes responsible? A ... such questions during a presentation at the University of Houston ... open to the public. Warren M. Washington, ...
... of the Flint Hills may no longer provide a ... birds, according to research by a Kansas State University ... three bird species common to the Flint Hills region ... in the face of extensive land-management practices like annual ...
Cached Biology News:Eugene-Springfield face Upper Willamette climate threats 2Eugene-Springfield face Upper Willamette climate threats 3Eugene-Springfield face Upper Willamette climate threats 4Prominent climate researcher to speak at UH on global warming March 5 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 2Birds in Flint Hills of Kansas, Oklahoma face population decline despite large habitat 3
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... virtually every research laboratory, the revolutionary Luminex ... accurately, inexpensively and in real time enhancing ... analysis system includes the Luminex 100, the ... xMAP technology which enables you to simultaneously ...
Biology Products: